Patient-derived stem-cell podocytes mimic genetic kidney scarring and mirror the patient's steroid response

Focal segmental glomerulosclerosis (FSGS) is a kidney lesion in which parts of the glomeruli, the kidney's filtering units, become scarred. Podocytes, the specialized cells that form the filtration barrier, lose their foot processes. Genetic variants are found in up to 60% of children with steroid-resistant nephrotic syndrome and about 30% of adults with FSGS, and more than 40 genes have been implicated. Many of these genes affect the podocyte actin cytoskeleton. Even people with the same mutation can have different disease features, and animal and standard cell models often miss the patient's genetic context. Patient-specific models could therefore help match patients to treatments and avoid ineffective ones.

The team studied a female patient under 30 with a heterozygous INF2 mutation (c.217G>A; G73S). INF2 mutations are a common cause of autosomal dominant FSGS, and she had a partial clinical response to steroids. They took dermal fibroblasts from a skin biopsy, reprogrammed them into human induced pluripotent stem cells (hiPSCs) using episomal methods, and differentiated them through nephron progenitor cells into podocytes (hiPSC-Podocytes). Cells from a healthy female donor served as the comparison. The methods described include chromosomal stability testing, Sanger sequencing of the mutation, qPCR, bulk RNA sequencing against podocyte marker gene sets, immunostaining, Western blotting, scanning electron microscopy and 3D culture. Quality control covered three hiPSC clones from the patient, and RNA sequencing used two clones per cell stage plus conditionally immortalized podocytes as a reference.

According to the abstract, the patient's hiPSC-Podocytes differed from the healthy donor's cells in several ways. They had shorter protrusions and lower levels of actin-associated markers, and INF2 protein levels were altered. Actin filaments were disrupted, with increased actin depolymerization. Two treatments were then tested. The actin-modulating agent Bis-T-23 improved the actin cytoskeleton in the patient's cells, and so did the steroid Solu-Decortin H (SDH). The steroid effect is consistent with the patient's partial clinical response to steroids.

The authors argue that hiPSC-Podocytes can capture patient-specific disease features and drug responses in a dish. Such a platform could support personalized treatment choices in genetic FSGS, including testing whether a given patient is likely to benefit from steroids or from actin-targeting drugs. The model is also meant to address how variable adult-onset genetic FSGS can be, even with identical mutations.

The evidence comes from one patient and one healthy donor, so the findings are a proof of concept. The text available for this summary included the introduction and part of the methods, and the quantitative results and discussion were not available. Whether in vitro drug responses reliably predict clinical outcomes, and whether the findings extend to other INF2 variants or other FSGS genes, remains to be shown.